Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden
- PMID: 15103452
- DOI: 10.1007/s00198-004-1623-4
Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden
Abstract
The aim of this study was to determine the threshold of fracture probability at which interventions became cost-effective in men and women, based on data from Sweden. We modeled the effects of a treatment costing $500 per year given for 5 years that decreased the risk of all osteoporotic fractures by 35% followed by a waning of effect for a further 5 years. Sensitivity analyses included a range of effectiveness (10-50%) and a range of intervention costs ($200-500/year). Data on costs and risks were from Sweden. Costs included direct costs, but excluded indirect costs due to morbidity. A threshold for cost-effectiveness of approximately $45,000/QALY gained was used. Cost of added years was included in a sensitivity analysis. With the base case ($500 per year; 35% efficacy) treatment in women was cost-effective with a 10-year hip fracture probability that ranged from 1.2% at the age of 50 years to 7.4% at the age of 80 years. Similar results were observed in men except that the threshold for cost-effectiveness was higher at younger ages than in women (2.0 vs 1.2%, respectively, at the age of 50 years). Intervention thresholds were sensitive to the assumed effectiveness and intervention cost. The exclusion of osteoporotic fractures other than hip fracture significantly increased the cost-effectiveness ratio because of the substantial morbidity from such other fractures, particularly at younger ages. We conclude that the inclusion of all osteoporotic fractures has a marked effect on intervention thresholds, that these vary with age, and that available treatments can be targeted cost-effectively to individuals at moderately increased fracture risk.
Similar articles
-
Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures.Curr Rheumatol Rep. 2007 Apr;9(1):50-6. doi: 10.1007/s11926-007-0022-1. Curr Rheumatol Rep. 2007. PMID: 17437668 Review.
-
Intervention thresholds for osteoporosis.Bone. 2002 Jul;31(1):26-31. doi: 10.1016/s8756-3282(02)00813-x. Bone. 2002. PMID: 12110408
-
Intervention thresholds for osteoporosis in the UK.Bone. 2005 Jan;36(1):22-32. doi: 10.1016/j.bone.2004.08.018. Epub 2004 Dec 15. Bone. 2005. PMID: 15663999
-
Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.Bone. 2014 Feb;59:105-13. doi: 10.1016/j.bone.2013.11.002. Epub 2013 Nov 12. Bone. 2014. PMID: 24231131
-
Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):359-66. doi: 10.1586/erp.10.53. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 20715911 Review.
Cited by
-
Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures.Curr Rheumatol Rep. 2007 Apr;9(1):50-6. doi: 10.1007/s11926-007-0022-1. Curr Rheumatol Rep. 2007. PMID: 17437668 Review.
-
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.Osteoporos Int. 2010 Mar;21(3):495-505. doi: 10.1007/s00198-009-0989-8. Epub 2009 Jun 30. Osteoporos Int. 2010. PMID: 19565175
-
The incidence and risk of hip fracture in Poland.Osteoporos Int. 2009 Aug;20(8):1363-7. doi: 10.1007/s00198-008-0787-8. Epub 2008 Nov 14. Osteoporos Int. 2009. PMID: 19009330
-
Frequency of Osteoporosis-Related Fractures in the Kingdom of Bahrain.Healthcare (Basel). 2024 Dec 12;12(24):2515. doi: 10.3390/healthcare12242515. Healthcare (Basel). 2024. PMID: 39765942 Free PMC article.
-
Bone mineral density measurements in vertebral specimens and phantoms using dual-layer spectral computed tomography.Sci Rep. 2017 Dec 13;7(1):17519. doi: 10.1038/s41598-017-17855-4. Sci Rep. 2017. PMID: 29235542 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical